VTVT - vTv Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

vTv Therapeutics Inc.

4170 Mendenhall Oaks Parkway
High Point, NC 27265
United States
336-841-0300
http://www.vtvtherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees56

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey B. KindlerExec. ChairmanN/AN/A1956
Mr. Stephen L. HolcombePres & CEO682.15kN/A1957
Mr. Rudy C. Howard CPA, B.A., CPAExec. VP & CFO484.55kN/A1958
Dr. Larry Douglas AltstielFormer Exec. VP & Chief Medical Officer582.2kN/A1950
Dr. Carmen Valcarce Ph.D.Chief Scientific Officer & Exec. VPN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.

Corporate Governance

vTv Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.